Zobrazeno 1 - 10
of 32
pro vyhledávání: '"R M, O'Bryan"'
Autor:
Janet O'Sullivan, George Thomas Budd, Silvana Martino, J Harris, J J Rinehart, R M O'Bryan, Richard G. Hahn, Martin D. Abeloff, Sylvan B. Green, Douglass C. Tormey
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 13(4)
PURPOSE To compare 1 year of therapy with continuous cyclophosphamide, methotrexate, fluorouracil (5-FU), vincristine, and prednisone (CMFVP) with a short course of treatment with a doxorubicin-based regimen in the postsurgical adjuvant treatment of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f820b461fc3b1809cce945f02ac14e0
https://pubmed.ncbi.nlm.nih.gov/7707108
https://pubmed.ncbi.nlm.nih.gov/7707108
Publikováno v:
Oncology nursing forum. 20(9)
There is increasing interest in evaluating the impact of cancer treatment and medical intervention on patient quality of life (QOL). This article reports the findings of a substudy that incorporated the Functional Living Index--Cancer in an ongoing a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8dfa305b81c7f10ea9a642c2b48646ae
https://pubmed.ncbi.nlm.nih.gov/8265446
https://pubmed.ncbi.nlm.nih.gov/8265446
Autor:
K S, Albain, J J, Crowley, L, Hutchins, D, Gandara, R M, O'Bryan, D D, Von Hoff, B, Griffin, R B, Livingston
Publikováno v:
Cancer. 72(4)
Survival after relapse or progression of small cell lung cancer (SCLC) is poor. The Southwest Oncology Group (SWOG) initiated a study of modulation of cyclophosphamide (Cy) resistance in this population. At study closure, the value of testing new reg
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2870177611d69c65e6c17a66ab472ec5
https://pubmed.ncbi.nlm.nih.gov/8393365
https://pubmed.ncbi.nlm.nih.gov/8393365
Autor:
J A, Gottlieb, S E, Rivkin, S C, Spigel, B, Hoogstraten, R M, O'Bryan, F C, Delaney, A, Singhakowinta
Publikováno v:
Cancer. 33(2)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f3d3d7f6012a36034dead9482e4a1ae6
https://pubmed.ncbi.nlm.nih.gov/4812769
https://pubmed.ncbi.nlm.nih.gov/4812769
Publikováno v:
Progress in clinical and biological research. 156
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::65f1631ba6142a479da48daa5916141c
https://pubmed.ncbi.nlm.nih.gov/6473443
https://pubmed.ncbi.nlm.nih.gov/6473443
Publikováno v:
Cancer treatment reports. 69(6)
Forty-five patients with stage III M1 non-small cell bronchogenic carcinoma were treated with vinblastine (1 mg/m2 by iv bolus twice a day on 2 consecutive days) plus mitomycin (10 mg/m2 on Day 1). This treatment was repeated at 3-week intervals for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f7d3fdc5309d34b49c815f82ef60751b
https://pubmed.ncbi.nlm.nih.gov/2990709
https://pubmed.ncbi.nlm.nih.gov/2990709
Publikováno v:
Cancer treatment reports. 69(5)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7c93920d0388df113b5a1dfadf05e293
https://pubmed.ncbi.nlm.nih.gov/3839167
https://pubmed.ncbi.nlm.nih.gov/3839167
Publikováno v:
Cancer treatment reports. 62(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dad71612cc03230ca0ca75685e6963a6
https://pubmed.ncbi.nlm.nih.gov/77189
https://pubmed.ncbi.nlm.nih.gov/77189
Autor:
J M, Quagliana, R M, O'Bryan, L, Baker, J, Gottlieb, F S, Morrison, H J, Eyre, W G, Tucker, J, Costanzi
Publikováno v:
Cancer treatment reports. 61(1)
A phase II study utilizing 5-azacytidine in the treatment of patients with solid tumors was carried out by the Southwest Oncology Group (SWOG-7208). Of 214 patients entered in the study 191 were eligible and 167 were evaluable. While initially they r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c82d555b0bbec8ed8d2b321f111d76b4
https://pubmed.ncbi.nlm.nih.gov/67893
https://pubmed.ncbi.nlm.nih.gov/67893
Publikováno v:
Cancer. 52(9)
A prospective randomized trial comparing streptozotocin, mitomycin C, and 5-FU (SMF) with mitomycin C and 5-FU (MF) in patients with advanced pancreatic cancer was performed. In patients with measurable disease the response rates were 34% (19/56) to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::847d73a45001cbe077483dfdf216efed
https://pubmed.ncbi.nlm.nih.gov/6225508
https://pubmed.ncbi.nlm.nih.gov/6225508